Press releases
Access archived Guidant press releases
Access archived BTG press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Oct 10, 2013
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the third quarter ended September 30, 2013 on
-
Oct 9, 2013MAJESTIC Trial To Study Self-Expanding DES System Designed To Treat Superficial Femoral Artery (SFA) Lesions
Launching a key clinical trial expected to serve as the foundation for global regulatory approvals, a physician in Auckland, New Zealand has performed...
-
Oct 8, 2013University of Pittsburgh independent study of contemporary heart failure devices highlights industry-leading Boston Scientific battery longevity
An independent and first-of-its-kind study from the University of Pittsburgh Medical Center, published online this week in EP EuroPace, shows there are...
-
Oct 8, 2013Re-ROUTE Trial Data Presented At VIVA 2013 Late-Breaking Session
The Boston Scientific (NYSE: BSX) OffRoad™ Re-Entry Catheter System demonstrated excellent performance in facilitating the treatment of complete...
-
Sep 17, 2013
ORBUSNEICH, BOSTON SCIENTIFIC SETTLE PATENT LITIGATION Fort Lauderdale, Fla. and Natick, Mass. (September 17, 2013) -- OrbusNeich Medical Inc. and Boston Scientific Corporation (NYSE: BSX) have...
-
Sep 17, 2013
Reinforcing its ongoing commitment to leadership in the global medical technology market, Boston Scientific Corporation (NYSE: BSX) today officially...
-
Sep 17, 2013REPRISE II Data Honored as Best Abstract 2013 at PCR London Valves Course
BOSTON SCIENTIFIC REPORTS favorable SIX-MONTH RESULTS from LOTUS™ valve system clinical trial REPRISE II Data Honored as Best Abstract 2013 at PCR London Valves Course Natick, Mass. (Sept. 17,...
-
Sep 12, 2013
In a significant milestone toward obtaining additional key regulatory approvals for the SYNERGY™ Stent System, Boston Scientific Corporation (NYSE:...
-
Sep 4, 2013Unlike Medications Alone, Bronchial Thermoplasty Provides Benefits That Last for Years Rather Than Hours
A breakthrough Boston Scientific technology for the treatment of severe asthma has been shown to be safe and effective over at least five years,...
-
Sep 4, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2013 Stifel Nicolaus Healthcare Conference on Sept. 11 in Boston. Jeff...
-
Sep 3, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2013 Morgan Stanley Global Healthcare Conference on Sept. 9 in New York....
-
Aug 21, 2013
Shanghai, China (August 21, 2013) - The first patient implants of the Boston Scientific Corporation (NYSE: BSX) COGNIS™ cardiac resynchronization therapy defibrillator (CRT-D) were successfully...
-
Aug 21, 2013
Boston Scientific Corporation (NYSE: BSX) continues to expand its electrophysiology (EP) offerings with U.S. Food and Drug Administration (FDA)...
-
Aug 19, 2013Innovative Bare Metal Stent Designed to Treat Peripheral Artery Disease
Boston Scientific Corporation (NYSE: BSX) has completed enrollment in the SuperNOVA trial – a global, single arm, prospective, multicenter trial...
-
Aug 13, 2013
Boston Scientific Corporation (NYSE: BSX) completed a public offering of $1.05 billion aggregate principal amount of its senior notes under the...
-
Aug 8, 2013
Boston Scientific Corporation (NYSE: BSX) announces the pricing of a public offering of $1.05 billion aggregate principal amount of its senior notes...
-
Jul 25, 2013
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.809 billion and adjusted earnings per share of $0.18 for the second quarter ended June...
-
Jul 24, 2013
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Rhythmia™ Mapping System, a...
-
Jul 24, 2013Next generation intravascular ultrasound catheter improves image quality and deliverability
The Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration clearance, CE Mark and Japan PMDA approval for its...
-
Jul 19, 2013First Patient Treated in OPTIMISE Clinical Trial Evaluating Safety, Efficacy of Occipital Nerve Stimulation Using Precision™ System
Boston Scientific Corporation (NYSE: BSX) has launched a clinical trial to determine whether occipital nerve stimulation (ONS) using the Precision™...
-
Jul 12, 2013Device Facilitates Delivery of Interventional Devices in Complex PCI Procedures
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration 510(k) clearance and CE Mark approval for the Guidezilla™...
-
Jul 11, 2013
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the second quarter ended June 30, 2013 on...
-
Jun 28, 2013Transaction to Accelerate Boston Scientific Expansion in Growing Electrophysiology Market
In a move that would significantly boost its capabilities in the fast-growing market for advanced electrophysiology procedures, Boston Scientific...
-
Jun 26, 2013
Paris (June 26, 2013) – The first patient implant of the Boston Scientific Corporation (NYSE: BSX) VITALIOTM pacemaker was performed at ZGT Hengelo in Hengelo, the Netherlands. In addition...
-
Jun 25, 2013
Paris (June 25, 2013) – Boston Scientific Corporation (NYSE: BSX) is launching a new family of pacemakers in Europe. These pacemakers monitor respiration, adjust pacing accordingly, and...
-
Jun 24, 2013Outcomes Follow Recent NICE Guidance Supporting Safety and Effectiveness of Subcutaneous Implantable Defibrillators
Paris (June 24, 2013) – The Boston Scientific Corporation (NYSE:BSX) S-ICD® (subcutaneous implantable defibrillator) System showed a significant reduction in major lead-related...
-
Jun 18, 2013VANTAGE Study Interim Data Presented at International Congress of Parkinson's Disease and Movement Disorders in Sydney
Patients with Parkinson's disease using the Boston Scientific Corporation (NYSE: BSX) Vercise™ DBS (deep brain stimulation) System showed a...
-
Jun 17, 2013First Implant of Company's Vercise Deep Brain Stimulation Device Designed to Treat Parkinson's
Boston Scientific Corporation (NYSE: BSX) announces the first implantation of its Vercise™ DBS System as part of the INTREPID clinical trial. ...
-
Jun 3, 2013
Boston Scientific Corporation (NYSE: BSX) continues to demonstrate its commitment to women's health by providing a research and education grant of more...
-
May 27, 2013GUIDE DBS is the World's First Deep Brain Stimulation Visual Simulation System
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for use of the GUIDE™ DBS System, the world's first deep brain stimulation...
-
May 24, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 38th Annual Deutsche Bank 2013 Healthcare Conference on May 30 in Boston....
-
May 22, 2013Interim Data from REDUCE-HTN Clinical Program Presented Today at EuroPCR
Boston Scientific Corporation (NYSE: BSX) today reported interim data from the REDUCE-HTN clinical program, which demonstrated a significant and sustained...
-
May 22, 2013New Data Presented In Late-Breaking Clinical Trial Session At EuroPCR Demonstrated Successful Deployment Of The Lotus™ Valve In The First 60 Patients With Minimal Paravalvular Regurgitation At 30 Days
Boston Scientific Corporation (NYSE: BSX) reports positive results from a pre-specified analysis of the first 60 patients enrolled in the REPRISE II trial...
-
May 22, 2013
Boston Scientific Corporation (NYSE: BSX) reports positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are...
-
May 21, 2013
Five-year data from the Asthma Intervention Research 2 (AIR2) clinical trial presented today demonstrated that the Boston Scientific Corporation (NYSE:...
-
May 17, 2013
Boston Scientific Corporation (NYSE:BSX) is scheduled to participate in Digestive Disease Week (DDW®) 2013, May 18-21 in Orlando, Fla. More than 24...
-
May 17, 2013
Boston Scientific Corporation (NYSE:BSX) is scheduled to participate at the annual EuroPCR Scientific Program May 21-24 in Paris. "We are pleased to...
-
May 15, 2013Study Evaluates Clinical Outcomes of Self-Expanding Metal Stents as a Bridge to Surgery
The first patient has been enrolled in a clinical investigation evaluating the use of the Boston Scientific Corporation (NYSE: BSX) WallFlex® Biliary...
-
May 10, 2013Industry-Leading Battery Life Reduces the Frequency of Replacement Surgery
New data from 100,438 patients with Boston Scientific Corporation (NYSE:BSX) implantable cardiac defibrillators (ICDs) and cardiac resynchronization...
-
May 10, 2013Company Offers Mapping System with IntellaMap Orion™ Mapping Catheter in Effort to Significantly Enhance Physician Treatment Options
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Rhythmia™ Mapping System, a next-generation 3D mapping and navigation...
-
May 9, 2013
Boston Scientific Corporation (NYSE: BSX) reports that the four-year follow-up data from the PROTECT AF clinical trial demonstrated the WATCHMAN® Left...
-
May 8, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2013 Healthcare Conference on May 15 in Las...
-
May 6, 2013
Boston Scientific Corporation (NYSE: BSX) completed a first-in-human clinical trial utilizing the IntellaTip MiFi™ XP Ablation Catheter for the...
-
May 3, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions...
-
Apr 25, 2013
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.761 billion and adjusted earnings per share of $0.16 for the first quarter ended March...
-
Apr 24, 2013Earth Week Celebration Focuses on 3,900-Panel Project at the Company’s International Distribution Center in Quincy
Natick, Mass. (April 24, 2013)—Boston Scientific Corporation (NYSE:BSX) celebrates Earth Week by inaugurating a 3,900-panel rooftop solar installation atop the company’s international...
-
Apr 15, 2013Innovative Device Quickly Anchors Leads and Catheters
Natick, Mass. (April 15, 2013) – Boston Scientific Corporation (NYSE: BSX) has acquired the fiXate™ Tissue Band and is launching the product in the United States. The fiXate Tissue Band is...
-
Apr 15, 2013
The first patient in the United States has been implanted with the Boston Scientific Corporation (NYSE: BSX) next generation ImageReady™ MR...
-
Apr 12, 2013World's First and Only System with Illumina 3D™ Software and 32 Contacts is Designed to Provide Pain Relief to a Broad Spectrum of Chronic Pain Patients
Boston Scientific Corporation (NYSE: BSX) has received approval by the U.S. Food and Drug Administration and is beginning a limited launch of the...
-
Apr 10, 2013
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2013 on...